Novartis focusing on disruptive technologies

The world’s largest pharmaceutical company, Novartis, has signalled their intent to move away from expensive manufacturing and towards new disruptive technologies like Crispr and CAR-T. While this means job losses in some manufacturing plants, jobs will also be created in cell and gene therapy manufacturing. This is great news for Mekonos, who have already been brought into Novartis facilities to develop their nano-robotic solution to cure diseases through cell therapy. Read more here: https://www.chemistryworld.com/news/novartis-to-cut-over-2000-jobs/3009579.article

Leave a Reply